Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week phase 3 study of fluticasone furoate + vilanterol versus vilanterol in COPD exacerbation reduction
2009-013063-19Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of fluticasone and vilanterol in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by GSK. Primary endpoint: Annual rate of moderate and severe exacerbations. Started Aug 2009; status: completed.
02
Drugs
fluticasonevilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2009-013063-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013063-19.